Opens in a new tab or window SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

The death of a nurse from North Lanarkshire has been linked to the use of a weight-loss drug recently approved for use on the ...

The average 15.4%-22.9% weight losses across the tirzepatide doses achieved initially in the trial were maintained throughout ...

This implies monthly maintenance doses, which would give it a big leg up on tirzepatide and semaglutide, which require weekly ...

As the battle against obesity and diabetes heats up, two new superstars are entering the ring in Spain - Mounjaro (also known ...

Novo Nordisk said on Friday its weight-loss drug met the main goals of a late-stage trial in patients with a type of fatty ...

A trial, targeted at people living with obesity from Britain to Puerto Rico, is the first head-to-head comparison of the weight-loss effects of the two blockbuster slimming jabs ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

The results from a sub-population of patients in Lilly's SURMOUNT-1 trial suggest that tirzepatide could provide an alternative that, at least in theory, could require less dramatic lifestyle changes.